Discovery of Novel HPK1 Inhibitors via Chemistry-Based Direct-to-Bioassay Screening and SAR Optimization.

Currently, efficient exploration of biologically relevant chemical space remains a significant challenge in lead discovery. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of T cell activation and a high-priority target for cancer immunotherapy. Herein, we report an integrated combinatorial chemistry-biological assay approach to accelerate lead identification for HPK1. First, an in-house HPK1 inhibitor library was fragmented and recombined in silico, followed by molecular docking, yielding preferred fragments. Then, selected fragments were assembled in a microplate, and the resulting compounds were used directly to perform biological assays, leading to the identification of lead compound 8b. Guided by four series of structure-activity relationship studies, our efforts afforded the optimized compound 53 (HPK1 IC50 = 1.7 nM). Compound 53 suppressed SLP76 phosphorylation, enhanced IL-2 release in the cell, and displayed low CYP/hERG risk. Moreover, compound 53 demonstrated potent in vivo antitumor efficacy in both mouse models, which highlighted its potential as a preclinical immunotherapy candidate.